Overall, it aims to streamline the clinical workflow and apply evidence-based assessment standards essential to the evaluation, treatment planning, and progress monitoring processes associated with neurodevelopmental disabilities and child mental health. The platform, known as Virtual IPM, will help to right-size individual care plans for each child and clinician capacity. Autism Analytica, a subsidiary of Quadrant Biosciences, has launched a clinical decision support software package designed to help clinicians better measure progress and improvements over time in a more standardized way. As a child works through their clinical interventions or therapies, measuring progress is key to adjusting treatment plans over time. While a virtual evaluation and genetic testing are two pivotal steps towards a treatment plan, the most important outcome for a family throughout this journey is ultimately an optimal treatment plan for their child's unique needs. Website: Hours: Monday, 9 AM - 8 PM, Tuesday, 9 AM - 7 PM, Wednesday and Thursday, 9 AM - 6 PM, Friday, 9 AM - 5 PM by appointment only. 122 Business Park Drive Suite 1 Utica NY 13502. Quadrant Laboratories, another core entity of the life sciences company, offers a saliva-based genetic test that can be sent directly to a child's home to assist with a family's journey toward answers. including ADHD, Autism Spectrum Disorders and related neuropsychological disorders. For example, the American Academy of Pediatrics recommends genetic testing for all children with Autism Spectrum Disorder. Her current practice specialties include treating individuals experiencing difficulties tied to depression, anxiety disorders, acute and chronic stressors, interpersonal relationship difficulties, behavioral problems, autism spectrum disorders, and ADHD. The national demand for our services is so significant that we're growing at 20 percent per month to meet parents' needs."īeyond an autism diagnosis, there are other important steps in the child's medical journey for families to consider. Richard Uhlig, CEO and Founder of Quadrant Biosciences, said, "As You Are physicians are evaluating over 1,000 new children every month. “This represents a major milestone for Quadrant and will ultimately help millions of children and families get appropriate treatment faster.”įor more information, visit Quadrant Biosciences.As You Are is an integral component of Quadrant Biosciences Inc., which has a mission to enhance the well-being of children and families, focusing on those facing developmental delays, including autism. “We are thrilled to have received this important designation and look forward to working collaboratively with the FDA to quickly advance this much needed technology,” says Richard Uhlig, founder and CEO of Quadrant Biosciences. Notably, the RNA features were implicated in physiologic processes related to ASD (axon guidance, neurotrophic signaling). The FDA Breakthrough Device Program is intended to help patients and healthcare providers receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. In the completely separate validation test set ( n 84 mean age 50 months 85 male 60 ASD), the algorithm maintained an AUC of 0.88 (82 sensitivity and 88 specificity). This novel test has the potential to substantially increase the efficiency of ASD identification, and lead to more rapid referral for early intervention services. Quadrant Biosciences, Syracuse, NY, has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the FDA for its Clarifi ASD autism saliva test.Ĭlarifi ASD is indicated for use in assessing the likelihood that a child has autism spectrum disorder (ASD) based on an evaluation of RNA epigenetic biomarkers in the saliva sample, as well as key patient characteristics.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |